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-   First systematic review of Sr-enriched biomaterials
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Introduction {#section8-2046-3758.66.BJR-2016-0311.R1}
============

The treatment of fractures carries important challenges, especially when impaired bone healing or bone loss is present. Osteoporosis is increasingly found in Western countries as the population ages, leading to a significant rise in the incidence of specific fractures, where these problems are particularly evident.^[@bibr1-2046-3758.66.BJR-2016-0311.R1]^ New treatment options are needed to overcome the challenges associated with management of this condition.

Biological and synthetic bone grafts have been used to manage bone defects, and autografts are the current benchmark.^[@bibr2-2046-3758.66.BJR-2016-0311.R1]^ However, due to their limited availability, the morbidity associated with harvest surgery and the relatively poor performance of synthetic materials, especially under osteoporotic conditions, there is a need for the development of effective and safer alternatives.^[@bibr3-2046-3758.66.BJR-2016-0311.R1],[@bibr4-2046-3758.66.BJR-2016-0311.R1]^ One proposed strategy has been the addition of osteo-inductive factors or osteoprogenitor cells to a bone substitute, in order to improve osteogenesis, particularly when impaired healing response is expected.^[@bibr5-2046-3758.66.BJR-2016-0311.R1]-[@bibr7-2046-3758.66.BJR-2016-0311.R1]^

Strontium (Sr) is a trace element that simultaneously stimulates bone formation and inhibits bone resorption.^[@bibr8-2046-3758.66.BJR-2016-0311.R1]-[@bibr10-2046-3758.66.BJR-2016-0311.R1]^ Nevertheless, the cardiovascular safety of oral Sr ranelate is still a matter of concern as a small but significant increase in non-fatal myocardial infarctions has been reported,^[@bibr11-2046-3758.66.BJR-2016-0311.R1]-[@bibr13-2046-3758.66.BJR-2016-0311.R1]^ leading to strict indications and restrictions for its use.^[@bibr11-2046-3758.66.BJR-2016-0311.R1]^

Several pre-clinical studies, performed in both normal and osteoporotic animal models, were consistent with previous *in vitro* studies, showing the beneficial effect of Sr ranelate in increasing bone architecture and bone strength.^[@bibr14-2046-3758.66.BJR-2016-0311.R1]-[@bibr16-2046-3758.66.BJR-2016-0311.R1]^ Accordingly, in order to enhance bone repair, Sr has recently been incorporated into different bone substitutes. This strategy aims to achieve a safer use of its osteoanabolic and anti-osteoclastic activity, as high concentrations are achieved locally, improving bone formation with less systemic impact. However, *in vivo* studies are scarce, and most reports do not present an adequate control group. Whether Sr-enriched materials are effective and safe is still a matter of debate, and more information on local Sr use is needed, with uniform criteria.

The aim of this study was to systematically review the *in vivo* effect of Sr in bone formation and/or remodelling, when incorporated into biomaterials.

Materials and Methods {#section9-2046-3758.66.BJR-2016-0311.R1}
=====================

A systematic search was performed in Pubmed and Scopus, using as a search strategy a combination of "Strontium", "Bone Regeneration", "Osteogenesis" (and similar terms such as (\"Bone Substitutes\" or Bone) and "Biomaterials" (and equivalents such as \"Biocompatible Materials\" or \"Materials Testing\" or \"Tissue Scaffolds\" or \"Biomimetic Materials\"). The search was limited by English language, human or other animal species (in Pubmed) and articles published after 1990 until July 2015. Additional papers were retrieved by non-systematic searches of relevant sources and screening of all retrieved article references ([Fig. 1](#fig1-2046-3758.66.BJR-2016-0311.R1){ref-type="fig"}).

![Flow diagram showing the study screening process.](bonejointres-06-366-g001){#fig1-2046-3758.66.BJR-2016-0311.R1}

Increased bone regeneration was defined based on increased bone formation and/or increased bone remodelling. Two comparison groups were previously defined, as an experimental group (E), which received a Sr-enriched biomaterial for evaluation of bone support or regeneration, and a control group (C) that received a similar Sr-free material. The groups had to differ only in Sr addition to the biomaterial in order to be included. Subgroups were also defined when specific conditions were present in both experimental and control groups (such as osteoporosis).

The study was conducted in two phases ([Fig. 1](#fig1-2046-3758.66.BJR-2016-0311.R1){ref-type="fig"}). In each phase, two independent reviewers (NN and DL) analysed the references and pooled according to predefined inclusion -- A) studies with original data, B) on Sr doped materials, C) used for bone support or regeneration, D) performed *in vivo* -- and exclusion criteria -- E) articles without a control group only different from experimental on Sr addition to the biomaterial, F) on Sr usage only as a substitute on implant coating material, and G) if full-text not available ([Fig. 1](#fig1-2046-3758.66.BJR-2016-0311.R1){ref-type="fig"}). In phase one, titles and abstracts were screened, and articles proceeded to the next phase upon inclusion of at least one reviewer. In phase two, full texts were assessed and disagreements were discussed between reviewers. When the full text was not available, authors were contacted and asked for a full-text copy. There was no article excluded due to unavailability of its full text.

Using an electronic form pre-developed by the authors, two investigators (NN and DL) performed data extraction. Qualitative results on the effect of Sr on bone regeneration were extracted independently of technique used for assessing Sr effect in each group. General results on implant effect were retrieved from individual papers, with data presented according to the amount of Sr in each biomaterial, time between material implantation and the analysis, and presence of concomitant conditions. The reported effect of Sr on bone formation, bone remodelling and its adverse effects were converted in a graphic summary table. Increased bone formation was considered as higher reported bone formation, total bone volume or other similar reference. Enhanced bone remodelling was defined as advanced maturation stage, higher biomaterial degradation, and central *versus* peripheral bone formation or similar.

When available, data on significance from each study were also gathered, with a statistically significant value defined as p \< 0.05. Data on gene or protein expression were collected upon availability.

This systematic review was conducted based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines.^[@bibr17-2046-3758.66.BJR-2016-0311.R1]^ The PRISMA statement checklist is available as Supplementary material.

Results {#section10-2046-3758.66.BJR-2016-0311.R1}
=======

A total of 572 references were retrieved after a literature search in Pubmed (210 references), and in Scopus (362 references), downgraded to 272 records after the application of exclusion criteria, the removal of duplicates, and the addition of hand and reference searches. In the title and abstracts selection phase, 231 records were excluded, mainly *in vitro* studies and studies on Sr's usage as a coating material, rather than as an implant for bone support or regeneration. In the full text selection phase, 41 papers were included. Four full texts were not available but were retrieved after contact with the authors. From these, 14 papers were excluded, mostly due to absence of control groups that received a Sr-free material, otherwise similar to the experimental material, and 27 articles were included in the final review ([Fig. 1](#fig1-2046-3758.66.BJR-2016-0311.R1){ref-type="fig"}).^[@bibr15-2046-3758.66.BJR-2016-0311.R1],[@bibr16-2046-3758.66.BJR-2016-0311.R1],[@bibr18-2046-3758.66.BJR-2016-0311.R1]-[@bibr42-2046-3758.66.BJR-2016-0311.R1]^

General article information is available in [Table I](#table1-2046-3758.66.BJR-2016-0311.R1){ref-type="table"} and general results on implant effect on Supplementary Table i. Rat models were used in 17 studies, nine were in rabbits and one in humans. The population of included studies ranged from four to 72 animals ([Table I](#table1-2046-3758.66.BJR-2016-0311.R1){ref-type="table"}). Apart from two articles, the primary goal of the papers was to assess the effect of Sr-enriched materials in the models studied. The majority of bone defects were created in long bones, mainly in the femur (n = 18). Most of the defects were drilled and bilateral, with some studies using the same animal in the control and experimental groups. Three studies used segmental defects ([Table I](#table1-2046-3758.66.BJR-2016-0311.R1){ref-type="table"}).

###### 

Description of the sample and methods of the studies included

  ID                                                     Animal                      n         Concomitant conditions                                                      Defect                 Material   Analysis                                                                               
  ------------------------------------------------------ --------------------------- ---- ---- --------------------------------------------------------------------------- ---------------------- ---------- ---------------- ------------------------------------- ------------------------------- ---------------------------------------------------------------------------------------------
  Banarjee^[@bibr18-2046-3758.66.BJR-2016-0311.R1]^      Sprague Dawley rats         8    4    H                                                                           Bilateral drilled      3          Distal Femur     ß-TCP-MgO/SrO cylinders               ß-TCP cylinders                 Hist
  Bose^[@bibr19-2046-3758.66.BJR-2016-0311.R1]^          Sprague Dawley rats         4    4    H                                                                           Bilateral drilled      3          Distal Femur     ß-TCP-MgO/SrO cylinders               ß-TCP cylinders                 Hist
  Boyd^[@bibr20-2046-3758.66.BJR-2016-0311.R1]^          Wistar rats                 12   12   O/H                                                                         Unilateral drilled     1          Midshaft Femur   Sr-Bioactive glass                    Bioactive glass                 Hist
  Cardemil^[@bibr21-2046-3758.66.BJR-2016-0311.R1]^      Sprague Dawley rats         32   32   O/H                                                                         Bilateral drilled      2.3        Distal Femur     Sr-CP granules                        HA granules                     Hist[\*](#table-fn1-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}; G
  Cheng^[@bibr22-2046-3758.66.BJR-2016-0311.R1]^         Sprague Dawley rats         22   21   O                                                                           Unilateral wedge       4          Distal Femur     Sr-CPC Xerogel particles Sr-Fe foam   CPC Xerogel particles Fe foam   PET
  Cheng^[@bibr23-2046-3758.66.BJR-2016-0311.R1]^         Sprague Dawley rats         7    7    O                                                                           Unilateral wedge       4          Distal Femur     Sr-CPC                                CPC                             PET
  Dagang^[@bibr24-2046-3758.66.BJR-2016-0311.R1]^        New Zealand White rabbits   2    2    H                                                                           Unilateral drilled     2.2        Distal Femur     Sr-HA cement                          HA cement                       Hist
  Gorustovich^[@bibr25-2046-3758.66.BJR-2016-0311.R1]^   Wistar rats                 15   15   H                                                                           Bilateral drilled      1.5        Tibia            Sr-Bioactive glass                    Bioactive glass                 Hist[\*](#table-fn1-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}
  Gu^[@bibr26-2046-3758.66.BJR-2016-0311.R1]^            New Zealand White rabbits   12   12   H                                                                           Unilateral segmental   15         Radius           Sr-CPP scaffold                       Sr-CPP scaffold                 Hist[\*](#table-fn1-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}
  Lin^[@bibr29-2046-3758.66.BJR-2016-0311.R1]^           Fisher rats                 3    3    O                                                                           Drilled (2 defects)    5          Calvarius        Sr-Ca Silicate scaffold               Ca Silicate scaffold            Hist[\*](#table-fn1-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}; µ-CT
  Mohan^[@bibr30-2046-3758.66.BJR-2016-0311.R1]^         New Zealand White rabbits   6    6    H                                                                           Unilateral segmental   15         Midshaft Ulna    Sr-CP cylinders                       HA cylinders                    Hist[\*](#table-fn1-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}; µ-CT
  Thormann^[@bibr16-2046-3758.66.BJR-2016-0311.R1]^      Sprague Dawley rats         15   15   O                                                                           Unilateral wedge       4          Distal Femur     Sr-CPC                                CPC                             Hist[\*](#table-fn1-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}; G; Immuno
  Tian^[@bibr31-2046-3758.66.BJR-2016-0311.R1]^          New Zealand White rabbits   24   24   H                                                                           Unilateral segmental   15         Radius           Sr-CPP scaffold                       CPP scaffold                    Hist[\*](#table-fn1-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}; radiograph; Immuno
  Wei^[@bibr32-2046-3758.66.BJR-2016-0311.R1]^           Wistar rats                 6    6    O                                                                           Bilateral drilled      3          Distal Femur     Sr Bioactive glass                    Bioactive glass                 Hist[\*](#table-fn1-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}; µ-CT
  Xie^[@bibr33-2046-3758.66.BJR-2016-0311.R1]^           New Zealand white rabbits   NI   NI   H                                                                           Unilateral             15         Femur            K/Sr-CPP scaffold                     CPP scaffold                    Hist[\*](#table-fn1-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"};
  Zhao^[@bibr35-2046-3758.66.BJR-2016-0311.R1]^          Sprague Dawley rats         6    6    H                                                                           Drilled (2 defects)    5          Calvarius        Sr Bioactive glass                    Sr Bioactive glass              Hist[\*](#table-fn1-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}; µ-CT
  Zhang^[@bibr34-2046-3758.66.BJR-2016-0311.R1]^         Wistar rats                 NI   NI   O                                                                           Bilateral drilled      3          Distal Femur     Sr Bioactive glass                    Bioactive glass                 Hist[\*](#table-fn1-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}; µ-CT; G; Immuno
  Baier^[@bibr15-2046-3758.66.BJR-2016-0311.R1]^         Sprague Dawley rats         30   30   O                                                                           Unilateral drilled     2          Distal Femur     Sr-CPC                                CPC                             Hist[\*](#table-fn1-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}
  Izci^[@bibr27-2046-3758.66.BJR-2016-0311.R1]^          Humans                      4    4    Other^[†](#table-fn2-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}^   Unilateral drilled     15         Cranium          Si-Sr-HA peg                          Si-HA peg                       µ-CT; Scintigraphy
  Li^[@bibr28-2046-3758.66.BJR-2016-0311.R1]^            Wistar rats                 20   20   H                                                                           Bilateral drilled      3          Proximal Tibia   Sr-CaS paste                          CaS paste                       Hist[\*](#table-fn1-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}; µ-CT; X-ray
  Jebahi^[@bibr36-2046-3758.66.BJR-2016-0311.R1]^        Wistar rats                 5    5    O                                                                           Unilateral drilled     3          Distal Femur     Sr Bioactive glass                    Bioactive glass                 Hist[\*](#table-fn1-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}
  Jebahi^[@bibr37-2046-3758.66.BJR-2016-0311.R1]^        Wistar rats                 5    5    O                                                                           Unilateral drilled     3          Distal Femur     Sr Bioactive glass                    Bioactive glass                 Hist[\*](#table-fn1-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}
  Kang^[@bibr38-2046-3758.66.BJR-2016-0311.R1]^          Japanese White rabbits      18   18   ON                                                                          Unilateral drilled     3          Proximal Femur   Sr-CPP scaffold and MNCs              CPP scaffold and MNCs           Hist[\*](#table-fn1-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}; radiograph; Immuno
  Tarafder^[@bibr39-2046-3758.66.BJR-2016-0311.R1]^      Sprague Dawley rats         4    4    H                                                                           Bilateral drilled      3          Distal Femur     ß-TCP-MgO/SrO cylinders               ß-TCP cylinders                 Hist[\*](#table-fn1-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}
  Tarafder^[@bibr40-2046-3758.66.BJR-2016-0311.R1]^      New Zealand White rabbits   2    2    H                                                                           Bilateral drilled      5.5        Distal Femur     ß-TCP-MgO/SrO cylinders               ß-TCP cylinders                 Hist[\*](#table-fn1-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}; Immuno
  Xie^[@bibr41-2046-3758.66.BJR-2016-0311.R1]^           New Zealand White rabbits   9    9    H                                                                           Unilateral             15         Femur Shaft      K/Sr-CPP scaffold                     CPP                             Hist[\*](#table-fn1-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}; radiograph; Immuno
  Zhang^[@bibr42-2046-3758.66.BJR-2016-0311.R1]^         New Zealand White rabbits   6    6    H                                                                           Unilateral drilled     6          Distal Femur     Sr-Borate Bioactive glass             Borate Bioactive glass          Hist[\*](#table-fn1-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}

Histomorphometry with Quantitative Analysis

Neoplastic or Trauma conditions

H, Healthy; O, Osteoporotic; ON, Osteonecrosis; MNCs, Autologous Bone Marrow Mononuclear Cells; NI, No Information; TCP, Tricalcium Phosphate; CP, Calcium Phosphate; HA, Hydroxyapatite; CPC, Calcium Phosphate Cement; CPP, Calcium Polyphosphate; CaS, Calcium Sulfate; Hist, Histology/Histomorphometry; I, Imagiological; G, Gene Expression; PET, Positron-Emission Tomography Scan; µ-CT, micro-Computed Tomography; Immuno, Immunohistochemistry.

The major concomitant condition studied in the animal models was osteoporosis; two studies included models with and without osteoporosis, and nine included only osteoporotic animals. One study was performed on animals with osteonecrosis. In the remaining ten studies, all animals were healthy ([Table I](#table1-2046-3758.66.BJR-2016-0311.R1){ref-type="table"}). The single article concerning humans included subjects who underwent a craniotomy due to different neoplastic and vascular conditions.

Time from implantation to analysis varied among the different studies, ranging from six days to 12 months. The studies used different materials. ([Table I](#table1-2046-3758.66.BJR-2016-0311.R1){ref-type="table"}). Two sets of studies used similar materials; eight on bioactive glass and five on hydroxyapatite (HA)/calcium phosphate (CP) cements. Sr concentration in the E group ranged from 0.1% to 22% (Supplementary Table i). All but three studies performed histologic and/or histomorphometric analysis. Radiological analysis such as micro-CT, PET scan, radiograph or scintigraphy were used in 12 papers for imaging ([Table I](#table1-2046-3758.66.BJR-2016-0311.R1){ref-type="table"}). Gene analysis and immunohistochemistry were available in two^[@bibr21-2046-3758.66.BJR-2016-0311.R1],[@bibr31-2046-3758.66.BJR-2016-0311.R1]^ and six^[@bibr16-2046-3758.66.BJR-2016-0311.R1],[@bibr31-2046-3758.66.BJR-2016-0311.R1],[@bibr34-2046-3758.66.BJR-2016-0311.R1],[@bibr38-2046-3758.66.BJR-2016-0311.R1],[@bibr40-2046-3758.66.BJR-2016-0311.R1],[@bibr41-2046-3758.66.BJR-2016-0311.R1]^ papers, respectively. Data on protein or gene expression are displayed in [Figure 2](#fig2-2046-3758.66.BJR-2016-0311.R1){ref-type="fig"}.

![Summary of study results on gene and protein expression. When different results from different study times were available, they were stated.](bonejointres-06-366-g002){#fig2-2046-3758.66.BJR-2016-0311.R1}

Results stated by each paper on the effect of the Sr-enriched biomaterial in bone formation and/or remodelling are displayed in Supplementary Table i. Although five studies reported analysis with multiple Sr concentrations, only in three did the authors gather information on the comparison between materials with different Sr content. In two studies, a significant superior overall effect was found with materials enriched with higher Sr concentration; the other study that looked at various concentrations found non-significant differences. Only one article reported the differential effect between healthy specimens and those with osteoporosis, finding an increased effect in osteoporotic animals (Supplementary Table i).

A graphic analysis on the result of the effect of the studied biomaterial in bone formation and remodelling, along with a summary of adverse effects reported by each paper, is presented in [Table II](#table2-2046-3758.66.BJR-2016-0311.R1){ref-type="table"}. Two articles studying bone formation reported a similar effect in the E and C groups; another one reported similar effects only in osteoporotic animals but an increased effect in healthy ones.^[@bibr20-2046-3758.66.BJR-2016-0311.R1]^ Baier et al^[@bibr15-2046-3758.66.BJR-2016-0311.R1]^ only found significant differences in the third month in both bone formation and remodelling. Cheng et al^[@bibr22-2046-3758.66.BJR-2016-0311.R1]^ studied three materials, with different compositions, but only one material, calcium phosphate cement (CPC), resulted in an increased effect on the experimental group. Apart from these, all other studies with analysis on bone formation found an increased effect of enriched material ([Tables II](#table2-2046-3758.66.BJR-2016-0311.R1){ref-type="table"} and [III](#table3-2046-3758.66.BJR-2016-0311.R1){ref-type="table"}).

###### 

Summary of general results on bone formation and bone remodelling from individual studies. Results are presented according to the content of Sr used in the biomaterial and the average time from implantation to evaluation

  Article                                                Strontium content     Time            Bone formation                                                                 Bone remodelling                                                               Adverse reaction                                                                                                                      Inflammatory reaction
  ------------------------------------------------------ --------------------- --------------- ------------------------------------------------------------------------------ ------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------- -----------------------
  Bose^[@bibr19-2046-3758.66.BJR-2016-0311.R1]^          1 wt%                 4 wks           Increased                                                                      NI                                                                                                                                                                                                                   
                                                                               8 wks           Increased                                                                      NI                                                                                                                                                                                                                   
                                                                               12 wks          NI                                                                             Increased                                                                                                                                                                                                            
                                                                               16 wks          NI                                                                             Increased                                                                                                                                                                                                            
  Tian^[@bibr31-2046-3758.66.BJR-2016-0311.R1]^          1 wt%                 4 wks           Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   Similar                                                                        L ↔                                                                                                                                   No
                                                                               12 wks          Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   Similar                                                                                                                                                                                                              
                                                                               16 wks          Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   Similar                                                                                                                                                                                                              
  Xie^[@bibr33-2046-3758.66.BJR-2016-0311.R1]^           2 wt%                 4 wks           Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   Similar                                                                                                                                                                                                              
                                                                               8 wks           Increased                                                                      Similar                                                                                                                                                                                                              
                                                                               12 wks          Increased                                                                      Increased                                                                                                                                                                                                            
                                                                               Overall         Increased                                                                      Increased                                                                      L ↔                                                                                                                                   No
  Dagang^[@bibr24-2046-3758.66.BJR-2016-0311.R1]^        5/10 wt%              4/8/12/24 wks   similar                                                                        Increased                                                                      L ↔                                                                                                                                   No
  Gorustovich^[@bibr25-2046-3758.66.BJR-2016-0311.R1]^   6 wt%                 30 days         NI                                                                             Similar                                                                        L ↔                                                                                                                                   No
  Gu^[@bibr26-2046-3758.66.BJR-2016-0311.R1]^            11.5 Ca/Sr MR         4 wks           NI                                                                             Increased                                                                      L ↔                                                                                                                                   No
                                                                               8 wks           NI                                                                             Increased                                                                      L ↔                                                                                                                                   No
                                                                               16 wks          Increased                                                                      Increased                                                                      L ↔                                                                                                                                   No
                                                                               Overall         Increased                                                                      Increased                                                                                                                                                                                                            
  Banarjee^[@bibr18-2046-3758.66.BJR-2016-0311.R1]^      0.25/1 wt%            4/16 wks        NI                                                                             Increased                                                                                                                                                                                                            
  Li^[@bibr28-2046-3758.66.BJR-2016-0311.R1]^            5/10 wt%              4 wks           Increased                                                                      Similar                                                                                                                                                                                                              
                                                                               8 wks           Increased                                                                      NI                                                                                                                                                                                                                   
                                                                               12 wks          Increased                                                                      Increased                                                                                                                                                                                                            
  Mohan^[@bibr30-2046-3758.66.BJR-2016-0311.R1]^         1.67 (Ca+Sr)/P MR     4/12 wks        Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   L ↔                                                                                                                                   No
  Zhao^[@bibr35-2046-3758.66.BJR-2016-0311.R1]^          10 wt%                8 wks           Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}                                                                                                                                         
  Izci^[@bibr27-2046-3758.66.BJR-2016-0311.R1]^          NI                    3/6/12 mths     Increased                                                                      Similar                                                                        L ↔                                                                                                                                   No
  Kang^[@bibr38-2046-3758.66.BJR-2016-0311.R1]^          11.5 Ca/Sr MR         4/8/12 wks      Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   L ↔                                                                                                                                   No
  Tarafder^[@bibr39-2046-3758.66.BJR-2016-0311.R1]^      1 wt%                 4 wks           Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   S (Similar Mg and Sr excretion in urine)                                                                                              
                                                                               8 wks           Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}                                                                                                                                         
                                                                               12 wks          Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   Increased                                                                                                                                                                                                            
                                                                               16 wks          Similar                                                                        NI                                                                                                                                                                                                                   
  Tarafder^[@bibr40-2046-3758.66.BJR-2016-0311.R1]^      1 wt%                 8/12 wks        Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}                                                                                                                                         
  Xie^[@bibr41-2046-3758.66.BJR-2016-0311.R1]^           11.5 Ca/Sr MR         4 wks           Similar                                                                        Increased                                                                      L ↔                                                                                                                                   No
                                                                               8 wks           Increased                                                                      Increased                                                                      L ↔                                                                                                                                   No
                                                                               12 wks          Increased                                                                      Increased                                                                      L ↔                                                                                                                                   No
  Zhang^[@bibr42-2046-3758.66.BJR-2016-0311.R1]^         9 mol% SrO            4/8 wks         Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   L ↔                                                                                                                                   No
  Boyd^[@bibr20-2046-3758.66.BJR-2016-0311.R1]^          0.14 SrO Mol Fract    4 wks           NI                                                                             Similar                                                                        L ↔                                                                                                                                   No
                                                         0.28 SrO Mol Fract    4 wks           Increased                                                                      NI                                                                             L ↔                                                                                                                                   No
                                                                                               Similar                                                                        NI                                                                                                                                                                                                                   
  Cardemil^[@bibr21-2046-3758.66.BJR-2016-0311.R1]^      NI                    6 days          Similar                                                                        NI                                                                             L ↔                                                                                                                                   Yes
                                                                               28 days         Similar                                                                        Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}                                                                                                                                         
                                                                               6 days          Similar                                                                        NI                                                                                                                                                                                                                   
                                                                               28 days         Similar                                                                        Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}                                                                                                                                         
  Wei^[@bibr32-2046-3758.66.BJR-2016-0311.R1]^           5 wt%                 2 wks           Similar                                                                        Similar                                                                                                                                                                                                              
                                                                               4 wks           Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   NI                                                                                                                                                                                                                   
                                                                               8 wks           Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   Increased                                                                                                                                                                                                            
  Thormann^[@bibr16-2046-3758.66.BJR-2016-0311.R1]^      0.123 Sr/Ca MR        6 wks           Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}                                                                                                                                         
  Zhang^[@bibr34-2046-3758.66.BJR-2016-0311.R1]^         2.5 wt%               2 wks           Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   S Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"} (Significant Sr increase in blood and urine samples)   
                                                                               4 wks           Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}                                                                                                                                         
                                                                               8 wks           Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   Increased / similar                                                                                                                                                                                                  
                                                         5 wt%                 2 wks           Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}                                                                                                                                         
                                                                               4 wks           Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}                                                                                                                                         
  Baier^[@bibr15-2046-3758.66.BJR-2016-0311.R1]^         NI                    1 mth           Similar                                                                        Similar                                                                        S increased (Similar spine and contralateral BMD)                                                                                     
                                                                               3 mths          Similar                                                                        Similar                                                                                                                                                                                                              
                                                                               6 mths          Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}                                                                                                                                         
  Lin^[@bibr29-2046-3758.66.BJR-2016-0311.R1]^           10 wt%                4 wks           Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}                                                                                                                                         
  Cheng^[@bibr22-2046-3758.66.BJR-2016-0311.R1]^         CPC -- 8.36 wt%       6 wks           Increased                                                                      NI                                                                                                                                                                                                                   
                                                         Xerogel -- 20 wt%                     Similar                                                                        NI                                                                                                                                                                                                                   
                                                         Iron Foam -- 22 wt%                   Similar                                                                        NI                                                                                                                                                                                                                   
  Cheng^[@bibr23-2046-3758.66.BJR-2016-0311.R1]^         8.36 wt%              6 wks           Increased                                                                      NI                                                                                                                                                                                                                   
  Jebahi^[@bibr36-2046-3758.66.BJR-2016-0311.R1]^        0.1%                  60 days         Increased                                                                      Increased                                                                      S (Similar blood cell counts and similar Ca and P blood levels)                                                                       
  Jebahi^[@bibr37-2046-3758.66.BJR-2016-0311.R1]^        0.1%                  90 days         Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   Increased[\*](#table-fn5-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}   L ↔                                                                                                                                   No

Shaded cells represent results from osteoporotic models.

Statistically significant difference between experimental and control

wt%, weight percentage; MR, Molar Ratio; Mol Fract, Molar Fraction; d, days; w, weeks; m, months; NI, No Information; L, Local; S, Systemic; CPC, Calcium Polyphosphate Cement; BMD, Bone Mineral Density ↔ Similar in experimental and control

###### 

Number of studies stating a specific result on bone formation and bone remodelling according to the time from implantation to evaluation. The single article on osteonecrosis was excluded from this analysis

  Time (wks)   Healthy   Osteoporosis                                                                                                                                                                       
  ------------ --------- -------------- --- --- --- --- ----------------------------------------------------------------------- ----------------------------------------------------------------------- --- ---
  1            1         1              0   0   0   1   1                                                                       0                                                                       0   0
  2            0         0              0   0   0   2   1                                                                       1                                                                       1   1
  4            14        3              8   5   8   6   3                                                                       3                                                                       1   3
  6            0         0              0   0   0   3   2^[‡](#table-fn9-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}^   3^[‡](#table-fn9-2046-3758.66.BJR-2016-0311.R1){ref-type="table-fn"}^   0   1
  8            10        1              8   1   7   3   0                                                                       3                                                                       0   3
  12           10        1              8   2   7   2   1                                                                       1                                                                       1   1
  16           5         1              2   1   3   0   0                                                                       0                                                                       0   0
  24           2         1              1   1   1   1   0                                                                       1                                                                       0   1
  48           1         0              1   1   0   0   0                                                                       0                                                                       0   0

experimental *versus* control

experimental *versus* control

Cheng, 2014^[@bibr35-2046-3758.66.BJR-2016-0311.R1]^ have different results with different materials

Of the studies with reports on bone remodelling, four showed similar results in experimental and control, four found an increased effect in experimental only in late study phases, and 17 reported an increased effect in the experimental group in all studied times ([Table III](#table3-2046-3758.66.BJR-2016-0311.R1){ref-type="table"}).

No study found a decreased effect of Sr addition in bone formation and/or regeneration when compared with controls. Overall, two articles had no report on bone remodelling, and another two did not report on bone formation.

Of the 17 articles with results on adverse effects of the implanted biomaterial, 13 reported similar local secondary effects in experimental and control. From these, 12 found no inflammatory reaction and one showed increased inflammation in both experimental and control. One article reported increased systemic effects of Sr application, with significantly raised levels of this ion in urine and blood samples, and the other three articles found no differences in systemic effects of Sr application.

Discussion {#section11-2046-3758.66.BJR-2016-0311.R1}
==========

This is the first systematic review that summarizes the *in vivo* effect in bone formation and remodelling of Sr-enriched biomaterials. Overall, Sr improves bone formation and remodelling, leading to a higher response when compared with similar Sr-free materials. Sr effect is present even in osteoporotic environments and some studies report greater effects in these models (Supplementary Table i). Our results are in agreement with other reviews on other enriching elements^[@bibr43-2046-3758.66.BJR-2016-0311.R1],[@bibr44-2046-3758.66.BJR-2016-0311.R1]^ and with previous *in vitro* results on Sr.^[@bibr9-2046-3758.66.BJR-2016-0311.R1],[@bibr45-2046-3758.66.BJR-2016-0311.R1]-[@bibr50-2046-3758.66.BJR-2016-0311.R1]^

Bone formation and remodelling: timing, models and health status {#section12-2046-3758.66.BJR-2016-0311.R1}
----------------------------------------------------------------

From the 25 articles with results on bone formation, 23 report some kind of improvement in the experimental group. Although not all state a benefit in all study points, we observed that the Sr effect appears mostly in the later stages of each study. In fact, a tendency to an increase in the number of studies reporting a stronger effect of Sr in bone formation in later study points is observed when analysing studies according to the time of evaluation, as seen in [Table III](#table3-2046-3758.66.BJR-2016-0311.R1){ref-type="table"}. Conclusions from studies with earlier assessment points therefore may be premature to differentiate the bone reaction between experimental and control. This may explain why Cardemil et al^[@bibr21-2046-3758.66.BJR-2016-0311.R1]^ found no differences, since the study ended just four weeks after implantation. However, some authors reported a significant improvement in experimental even at weeks two and four. One can argue that response to Sr may be influenced by the amount of time that the bone is exposed to this component.

Few studies report similar effects on bone formation in experimental and control, and for each study time the number of studies reporting increased effect in experimental *versus* control is at least similar to the number of studies stating equal effects. When considering bone remodelling, fewer results are available, and the number of studies reporting increased bone formation and remodelling in experimental is only superior after six weeks. These results on bone formation and remodelling are valid, independent of the model's health status. This confirms previous reports on Sr, as a stimulator of bone differentiation and osteogenesis.^[@bibr9-2046-3758.66.BJR-2016-0311.R1],[@bibr45-2046-3758.66.BJR-2016-0311.R1]-[@bibr50-2046-3758.66.BJR-2016-0311.R1]^ However, the optimal conditions for its usage are yet to be determined, in order to maximize its beneficial effects.

Moreover, no study showed decreased bone formation or remodelling in experimental, in any time period, for either healthy or diseased models. The presence of a beneficial effect of Sr even in osteoporotic models, may enhance its therapeutic value, since osteogenesis impairment is a major challenge in this condition.^[@bibr4-2046-3758.66.BJR-2016-0311.R1]^

Biomaterials {#section13-2046-3758.66.BJR-2016-0311.R1}
------------

We decided to consider Strontium Calcium Phosphate (SrCaPO~4~) and Sr-HA as similar materials, since SrCaPO~4~ results from incorporation of Sr into HA.^[@bibr30-2046-3758.66.BJR-2016-0311.R1]^ However, it is known that incorporation of Sr into HA may impact its solubility,^[@bibr21-2046-3758.66.BJR-2016-0311.R1]^ which may partially explain why only articles using biomaterials with Sr-HA showed no improved effect in E. Although Mohan et al^[@bibr30-2046-3758.66.BJR-2016-0311.R1]^ found a significant improvement in E using HA as a base material, we cannot make any comparison with the two other articles using HA since different defect models were used.

The rate of Sr release from the biomaterial was also identified as a possible factor impacting its activity, since osteoblast-like cells use the strontium released from the biomaterial to synthesize their mineralised extracellular matrix.^[@bibr51-2046-3758.66.BJR-2016-0311.R1]^ Thormann et al^[@bibr16-2046-3758.66.BJR-2016-0311.R1]^ showed higher Sr concentrations in zones of increased bone formation, supporting this finding. More studies on the relationship between Sr concentrations and bone formation are needed to clarify this theory.

Sr content {#section14-2046-3758.66.BJR-2016-0311.R1}
----------

Our study also showed that even small amounts of Sr might be enough to have an impact on both bone formation and remodelling since some authors found significant differences with only 0.1% of this component.^[@bibr36-2046-3758.66.BJR-2016-0311.R1],[@bibr37-2046-3758.66.BJR-2016-0311.R1]^ However, two of the three authors who specifically compared different Sr percentages found an increased overall response with higher concentrations,^[@bibr24-2046-3758.66.BJR-2016-0311.R1],[@bibr34-2046-3758.66.BJR-2016-0311.R1]^ confirming previous *in vitro* reports.^[@bibr52-2046-3758.66.BJR-2016-0311.R1]^ The other author reported similar results between E and C.^[@bibr28-2046-3758.66.BJR-2016-0311.R1]^ All three authors agree that the optimum dose of Sr is yet to be discovered, since it can impact both the bone response and material properties.^[@bibr24-2046-3758.66.BJR-2016-0311.R1],[@bibr28-2046-3758.66.BJR-2016-0311.R1],[@bibr34-2046-3758.66.BJR-2016-0311.R1]^

Gene expression {#section15-2046-3758.66.BJR-2016-0311.R1}
---------------

The available information on Sr impact on gene expression can be seen in [Figure 2](#fig2-2046-3758.66.BJR-2016-0311.R1){ref-type="fig"}. Broadly speaking, little variation was found but a decrease in the pro-inflammatory cytokine Il-6, a stimulator of osteoclast recruitment and bone reabsorption, related to altered bone metabolism, may help to explain the Sr effect as a promoter of bone formation and remodelling.^[@bibr53-2046-3758.66.BJR-2016-0311.R1]^ The increase in genes and proteins involved in these processes, such as osteocalcin and bone morphogenetic protein supports our reported results of Sr's bone forming effects.^[@bibr53-2046-3758.66.BJR-2016-0311.R1]^

Side effects {#section16-2046-3758.66.BJR-2016-0311.R1}
------------

As previously stated, Sr systemic side effects were responsible for a downgrading of its interest for the scientific community, and for a move to local application of this component.^[@bibr11-2046-3758.66.BJR-2016-0311.R1]-[@bibr13-2046-3758.66.BJR-2016-0311.R1]^ Our review found only four studies on the systemic repercussion of local Sr application. While one study reported increased levels of Sr in both urine and blood samples,^[@bibr34-2046-3758.66.BJR-2016-0311.R1]^ another showed similar urinary excretion of this element.^[@bibr39-2046-3758.66.BJR-2016-0311.R1]^ The other two studies found no difference between experimental and control groups.^[@bibr15-2046-3758.66.BJR-2016-0311.R1],[@bibr36-2046-3758.66.BJR-2016-0311.R1]^ One study reported increased values of serum Sr, but no comparison with C was performed, and the authors state that the concentration was 100 times lower than that needed to produce systemic effects.^[@bibr15-2046-3758.66.BJR-2016-0311.R1]^ Nevertheless, the pathological effects of these findings are not well known and still a matter of debate for future studies. A total of 13 reported on local effects, but no differences were found from C, and only one study found an increased inflammatory reaction, both in experimental and control. Also, the short follow-up of most included studies impacts the ability to trace reliable conclusions on the adverse long-term effect of Sr.

Methodologies and limitations {#section17-2046-3758.66.BJR-2016-0311.R1}
-----------------------------

The methods of the included studies were highly variable. First, different animal models were used, and only nine studies presented the same animal species. This can impact the results since it is known that both bone architecture and the regeneration process are different among species, posing problems when it comes to comparisons between studies.^[@bibr54-2046-3758.66.BJR-2016-0311.R1],[@bibr55-2046-3758.66.BJR-2016-0311.R1]^ Also, all studies in animals used small species, with known differences in bone macroscopic, microscopic and remodelling properties when compared with humans.^[@bibr55-2046-3758.66.BJR-2016-0311.R1]^ Although larger animals, like dog and sheep, present a more reliable model, they may pose more ethical, housing, handling and availability issues.^[@bibr54-2046-3758.66.BJR-2016-0311.R1],[@bibr55-2046-3758.66.BJR-2016-0311.R1]^ These variations between species may, at least partially, explain the different responses to the biomaterial found in the included studies. Only one article studied the application of Sr-enriched biomaterials in humans.^[@bibr27-2046-3758.66.BJR-2016-0311.R1]^ Although achieving an increased effect of Sr, the constraints of study design impact our ability to draw reliable conclusions.

Even in the same species, defects differ in size, type and location. All studies that created a segmental defect found an increased effect of Sr on both bone formation and remodelling independent of the study time. This did not happen with other types of defect. One may suppose that segmental defects, with a greater impact on bone macrostructure, may influence either bone response, with the possibility of stimulation of a quicker reaction, or the ability to retrieve reliable results in the early stages. Guidelines are not available regarding the appropriate defect needed for each case, and a recent study pointed out that differences in defect creation impact the bone response.^[@bibr54-2046-3758.66.BJR-2016-0311.R1]^ More accurate and homogeneous lines of conduct are essential for the future design of comparable and reproducible study models.

As stated before, time to healing evaluation is variable among studies. Previous reports stated that fracture consolidation with a neocortex consisting of woven and lamellar bone is usually completed in an average of five to six weeks. However, different models, and even different bone defects, can alter this timeline.^[@bibr56-2046-3758.66.BJR-2016-0311.R1]^

Different methods for evaluation of response were found. Qualitative measurements, such as histology or imaging techniques, are observer-dependent subjective analyses, introducing bias to the reported results.^[@bibr57-2046-3758.66.BJR-2016-0311.R1]^ This may explain why Dagang, Kewei and Yong^[@bibr24-2046-3758.66.BJR-2016-0311.R1]^ found no significant differences between E and C since this study performed only a histological analysis.

Our review has other limitations. Only 27 studies were retrieved. From these, 20 presented numeric results from histological analysis, but a quantitative synthesis of data was not possible since only a few performed comparable measurements of bone formation and/or remodelling. These studies, along with those with only qualitative data, were included in the review, allowing a broad qualitative assessment of published studies but no meta-analysis was performed. The definition of bone formation and bone remodelling was subjective and different in each study. Two reviewers performed the selection of relevant results but the absence of strict definitions increases the risk of bias. Many studies, especially those with only qualitative data assessment, did not present the significance of the comparisons, increasing the subjectivity of their interpretation.

Future studies must follow appropriate protocols, and guidelines on results assessment for each technique should be drafted. The application of Sr in larger animal models, with longer follow-up times, is needed, with an appropriate monitoring of long-term local and systemic side effects. More studies on the comparison between diseased and healthy models, and between different Sr concentrations, would be of great importance to better understand the potentiality of this element.

In conclusion, Sr is an apparently safe and effective doping material for stimulating bone formation and remodelling. Its effect may be more pronounced and variable over time according to the concentration applied. Additionally, its benefit in osteoporotic models raises the possibility of its therapeutic value. However, the plethora of methods, measurements and protocols found in individual studies impacts the ability to perform a reliable data synthesis and analysis on Sr effect. It is important to develop adequate models and follow consistent guidelines of research in future studies, in order to better define the therapeutic application of this element.
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